Unum Therapeutics (NASDAQ: UMRX) is one of 553 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Unum Therapeutics to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
This table compares Unum Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Unum Therapeutics Competitors||-1,775.73%||-94.19%||-27.76%|
47.4% of Unum Therapeutics shares are held by institutional investors. Comparatively, 45.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 15.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Unum Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500. Comparatively, Unum Therapeutics’ peers have a beta of 1.33, indicating that their average stock price is 33% more volatile than the S&P 500.
Earnings & Valuation
This table compares Unum Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Unum Therapeutics||$9.73 million||-$34.53 million||-2.37|
|Unum Therapeutics Competitors||$2.14 billion||$226.59 million||-3.45|
Unum Therapeutics’ peers have higher revenue and earnings than Unum Therapeutics. Unum Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current ratings for Unum Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Unum Therapeutics Competitors||4681||13293||28038||1007||2.54|
Unum Therapeutics presently has a consensus target price of $17.25, suggesting a potential upside of 422.73%. As a group, “Pharmaceutical preparations” companies have a potential upside of 61.90%. Given Unum Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Unum Therapeutics is more favorable than its peers.
Unum Therapeutics beats its peers on 7 of the 13 factors compared.
About Unum Therapeutics
Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL). Its product portfolio also includes ACTR087 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r NHL; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; ACTR707 used in combination with trastuzumab that is in Phase I clinical trials for treating HER2+ solid tumor cancers; and BOXR1030, which is in pre-clinical stage, targets GPC3, an oncofetal antigen expressed in various tumors, including liver and lung cancers. The company has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. Unum Therapeutics Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.